Europska Unija - latvijski - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. izņemot tikko diagnosticēta cml hroniskā fāzē, nav kontrolētos pētījumos, kas liecina par klīnisko ieguvumu vai palielina izdzīvošanas šo slimību. .

Latvija - latvijski - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - mikofenolāta mofetils - apvalkotā tablete - 500 mg

Latvija - latvijski - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia "nutricia" - pulveris

Latvija - latvijski - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia ''nutricia'' 40103070928 gustava zemgala gatve 74, rīga, lv-1039, latvija - pulveris - cits - Īpašiem medicīniskiem nolūkiem paredzēta pārtika

Latvija - latvijski - Pārtikas un veterinārais dienests, Zemkopības ministrija

nutricia, sia 40103070928 skanstes iela 12, rīga, lv-1013 - pulveris - cits - diētiskai lietošanai, kad nepieciešama papildus l-citrulīna uzņemšana, kad ir ornitīntranskarbamilāzes (oct) un karbamilfosfātsintetāzes (cps) trūkums

Latvija - latvijski - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvija - latvijski - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - rivaroksabans - apvalkotā tablete - 10 mg

Latvija - latvijski - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - rivaroksabans - apvalkotā tablete - 15 mg

Latvija - latvijski - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - rivaroksabans - apvalkotā tablete - 20 mg

Latvija - latvijski - Zāļu valsts aģentūra

pharma nord aps, denmark - glikozamīns - kapsula, cietā - 400 mg